

FXI / FXIa: Rethinking Anticoagulation Through Mechanistic Clarity

Strategic White Paper (Simplified Edition)

Positioning

This white paper is not a prediction.

It is a judgment framework that helps teams see what is objectively true within complex mechanisms and clinical boundaries.

Sources

- Closed-door expert discussions (without identifiable information)
- Publicly available evidence
- New target judgment frameworks
- Cross-disciplinary perspectives
- Clinical pathway trends in China
- China-specific judgment frameworks
- Common misconceptions in MNC judgment in China
- Judgment risks foreseeable in the next five years

Simplified Extract

- **Mechanism Window:** FXI/FXIa inhibition provides new clarity in anticoagulation boundaries, identifying it as an amplification node for clinical effects, supported by genetic and disease-context evidence.
- **Indication Matrix:** Through perspectives from cardiology, nephrology, and other disciplines, clinical effect predictability can be distinguished within specific domains of thrombosis, enabling targeted differentiation and optimal outcomes rather than simple data accumulation.
- **Risk Calibration:** Structured judgment pathway for foreseeable regulatory acceptance in China over the next five years.

Boundaries

We do not reference:

- Specific companies
- Specific products
- Confidential information

Our goal is to provide neutral, structured, expert-informed clarity.

Our white papers do not predict outcomes; they clarify structures.

Copyright

© 2026 Golden Changes Pharmaceutical Co., Limited

All rights reserved.

First Edition, 2026

Published in Hong Kong

www.goldenchanges.org

This document is the Simplified Public Edition of the FXI/FXIa Mechanistic Judgment Framework.

The full edition is reserved for closed-door expert discussions and internal judgment.